Lobular Breast Cancer Alliance advocate and patient Diane Mapes tells her story of being diagnosed with sneaky lobular breast cancer and why we need more research to better understand this disease. Reprinted with permission from Healthline, Inc.
We are sad to announce that the 2nd ILC Symposium organizing committee – including the Lobular Breast Cancer Alliance advocates – have canceled the 2nd
2nd ILC Symposium and Lobular Advocate Boot Camp Canceled Read More »
The Lobular Breast Cancer Alliance presented a research poster at the San Antonio Breast Cancer Symposium (SABCS) December 11, 2019 sharing the findings of a
LBCA Presents Survey Results at SABCS 2019 Read More »
Know where ILC can spread and the symptoms of metastasis
Metastatic Sites and Symptoms of ILC Read More »
Postmenopausal women who have been diagnosed with invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a multi-site clinical trial. This clinical trial will compare how lobular breast tumors respond to three different commonly prescribed, effective medications that are currently being used to treat breast cancer.Â
Clinical Trial: Endocrine Response in Pre-Surgical ILC Patients Read More »
Susan G. Komen partnered with the Lobular Breast Cancer Alliance to host a webinar Lobular Breast Cancer: A Different Disease. This webinar is geared towards
Research Advocate Education: Lobular Breast Cancer- A Different Disease Read More »
Patients with Metastatic Lobular Breast Cancer (cancer has spread beyond the breast to other parts of the body) have a unique opportunity to advance critical research by participating in the Metastatic Breast Cancer Project’s ILC initiative.
Patients with ILC Mets Needed to Advance Research Read More »
The Cleveland Clinic Breast Cancer Program hosted a patient learning event Lobular Breast Cancer: An Evening of Learning on August 22, 2019. This two hour
Educational Recording: ILC: An Evening Of Learning Cleveland, 2019 Read More »
The American Association of Clinical Oncologists (ASCO) held its annual meeting in Chicago in June 2019. Two advocates from LBCA’s Steering Committee attended this leading
LBCA at ASCO 2019 Read More »
by LBCA Steering Committee member Diane Mapes (aka @double_whammied) At the 2019 American Association of Clinical Oncology (ASCO) annual meeting in Chicago, the LBCA was
Advocate’s Report ASCO 2019: Q & A with Dr. Peter Lucas Read More »
The Lobular Breast Cancer Alliance partnered with SHARE Cancer Support to host an advocate-led roundtable discussion on August 28th, 2019. This hour-long webinar features LBCA
Educational Recording: Overview of ILC and Advocacy August, 2019 Read More »
The Great Lakes Breast Cancer Symposium (GLBCS) was held May 2 – 4th, 2019 in Columbus Ohio. Three lobular advocates and steering committee members from
Great Lakes Breast Cancer Symposium: Video interviews with researchers, Advocates Read More »
March, 2019: The Lobular Breast Cancer Alliance (LBCA) joined the Metastatic Breast Cancer Alliance (MBC Alliance) as a non-profit organization member. LBCA will work collaboratively
LBCA joins the Metastatic Breast Cancer Alliance Read More »
Leigh Pate of Seattle, WA received the Beth Caldwell Leadership and Advocacy Breakthrough Award. The award was presented at the Northwest Metastatic Breast Cancer Conference
LBCA Founder Receives Leadership Award Read More »
Women who have been diagnosed with Stage 1 – 3 invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a clinical trial. This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies.
PELOPS: Clinical Trial with Palbociclib for Pre-surgical ILC Patients Read More »
"*" indicates required fields
